| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 414-419, Copyright © 1993 by American Association for Clinical Chemistry
WD Fraser, J Robinson, R Lawton, B Durham, SJ Gallacher, IT Boyle, GH Beastall and FC Logue
University Department of Clinical Chemistry, Royal Liverpool University Hospital, UK.
Parathyroid hormone-related protein (PTHrP) was measured in plasma by a new immunoradiometric assay (IRMA) from Nichols Institute. The assay is specific for PTHrP and shows excellent parallelism when measuring keratinocyte fluid, samples with high PTHrP content, and PTHrP- supplemented plasma. A precision profile established the assay detection limit at 0.7 pmol/L. PTHrP was unstable in plasma, but the degradation rate was patient-specific. Because delay in separation resulted in loss of PTHrP immunoreactivity, samples were collected into tubes containing protease inhibitors (aprotinin, leupeptin, pepstatin, and EDTA) and separated within 30 min. Among normal subjects, 78% had PTHrP values greater than the detection limit; the reference range established was < 0.7-2.6 pmol/L. Of patients with hypercalcemia associated with malignancy, 46% had PTHrP > 2.6 pmol/L. PTHrP was increased in patients with breast (73%), genitourinary (64%), or lung (46%) malignancy but was rarely above normal in patients with hematological (29%) or gastrointestinal (33%) malignancy. PTHrP and nephrogenous cyclic adenosine monophosphate (NcAMP) were strongly correlated (r = 0.63, P < 0.01) in 37 patients with PTHrP values greater than the detection limit, but 8 patients had PTHrP and parathyroid hormone [PTH(1-84)] values below the limit of detection with inappropriate or increased NcAMP. Five of these eight patients had small cell carcinoma of lung. These patients may have secreted a factor that is not detected by the IRMAs of PTHrP or PTH used in this study but that produces hypercalcemia by means of cAMP-mediated mechanisms.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  K. Ogino, K. Ogura, Y. Kinugasa, Y. Furuse, K. Uchida, M. Shimoyama, T. Kinugawa, S. Osaki, M. Kato, Y. Tomikura, et al. Parathyroid Hormone-Related Protein Is Produced in the Myocardium and Increased in Patients with Congestive Heart Failure J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4722 - 4727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Tovar Sepulveda, X. Shen, and M. Falzon Intracrine PTHrP Protects against Serum Starvation-Induced Apoptosis and Regulates the Cell Cycle in MCF-7 Breast Cancer Cells Endocrinology, February 1, 2002; 143(2): 596 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshida, H. Sakamoto, T. Horiuchi, S. Yamamoto, A. Suematsu, H. Oda, and Y. Koshihara Involvement of Prostaglandin E2 in Interleukin-1{{alpha}}-Induced Parathyroid Hormone-Related Peptide Production in Synovial Fibroblasts of Patients with Rheumatoid Arthritis J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3272 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Falzon and P. Du Enhanced Growth of MCF-7 Breast Cancer Cells Overexpressing Parathyroid Hormone-Related Peptide Endocrinology, May 1, 2000; 141(5): 1882 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Dumon, T. Jensen, B. Lueddecke, J. Spring, J. Barle, and J.-J. Body Technical and Clinical Validation of an Immunoradiometric Assay for Circulating Parathyroid Hormone-related Protein Clin. Chem., March 1, 2000; 46(3): 416 - 418. [Full Text] [PDF]
|
|
|
|
|
|
M. Falzon and J. Zong The Noncalcemic Vitamin D Analogs EB1089 and 22-Oxacalcitriol Suppress Serum-Induced Parathyroid Hormone-Related Peptide Gene Expression in a Lung Cancer Cell Line Endocrinology, March 1, 1998; 139(3): 1046 - 1053. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
